Pharmaceutical intelligence for Beijing Biostar Pharmaceuticals Co., Ltd. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 1

Recent signals(1)

ClinicalJuly 7, 2026

Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer

A randomized controlled study is evaluating the efficacy of Utidelone Capsule versus Utidelone Injection in combination with Capecitabine for HER-2 negative advanced breast cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 7, 2026

Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer

A randomized controlled study is evaluating the efficacy of Utidelone Capsule versus Utidelone Injection in combination with Capecitabine for HER-2 negative advanced breast cancer.

Competitive activity

No signals indexed for this entity yet.

Assets

Capecitabine →

Therapeutic areas

Breast Cancer →

Oncology →

Oncology · Breast Cancer →

Indications

Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.